GlassScriptPhysician profile
Debra A Walz
NPI 1194045765
$6,828.65
in general payments reported to CMS, 2019-2025
51 companies · $417 in 2025
The $417 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $136 · 2022: $573 · 2023: $2,733 · 2024: $2,969 · 2025: $417.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,057 · Education: $1,062.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,057.06 |
| Education | $1,061.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $699.96 | 2022-2024 | Darzalex, Carvykti, Rybrevant |
| Merck Sharp & Dohme LLC | $571.24 | 2022-2025 | Keytruda, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $544.40 | 2023-2025 | Opdivo, Onureg, Reblozyl |
| Novartis Pharmaceuticals Corporation | $449.12 | 2023-2024 | |
| Daiichi Sankyo INC. | $400.87 | 2022-2024 | Enhertu, Vanflyta |
| Abbvie INC. | $334.96 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $334.53 | 2022-2024 | Tagrisso, Calquence, Imfinzi |
| Astellas Pharma US INC | $330.85 | 2023-2024 | Padcev |
| Eisai INC. | $275.21 | 2022-2024 | |
| Pfizer INC. | $274.77 | 2022-2024 | |
| Incyte Corporation | $236.46 | 2022-2024 | Jakafi, Monjuvi, Pemazyre |
| Regeneron Healthcare Solutions, INC. | $188.24 | 2022-2025 | Libtayo |
| Takeda Pharmaceuticals U.S.A., INC. | $165.32 | 2023-2025 | Iclusig, Ninlaro, Fruzaqla |
| Seagen INC. | $158.11 | 2023-2024 | Padcev |
| Myriad Genetic Laboratories, INC. | $152.28 | 2021-2023 | Myrisk |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $132.72 | 2022-2025 | Zejula, Jemperli, Ojjaara |
| Gilead Sciences, INC. | $106.96 | 2023-2024 | Trodelvy |
| Celgene Corporation | $100.97 | 2022-2024 | Reblozyl, Opdualag |
| Puma Biotechnology, INC. | $92.18 | 2023-2024 | |
| Emd Serono, INC. | $72.27 | 2023-2024 | Bavencio |
| Lilly USA, LLC | $67.10 | 2023-2024 | Jaypirca, Retevmo, Verzenio |
| Genmab U.S., INC. | $66.86 | 2023-2024 | Tivdak, Epkinly |
| Adaptive Biotechnologies Corporation | $65.71 | 2023-2024 | Clonoseq |
| Pharmacosmos Therapeutics INC. | $63.90 | 2022-2023 | Monoferric |
| Amgen INC. | $62.87 | 2023 | Kyprolis, Lumakras, Blincyto |
| Pharmacyclics LLC, An Abbvie Company | $60.00 | 2023 | Imbruvica, Epkinly |
| Sobi, INC | $57.29 | 2022-2024 | |
| Karyopharm Therapeutics INC. | $51.05 | 2022-2024 | Xpovio |
| Genentech USA, INC. | $50.22 | 2024 | Phesgo, Tecentriq, Alecensa |
| Adc Therapeutics America, INC. | $48.12 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $47.84 | 2024 | |
| Array Biopharma INC | $46.07 | 2023-2024 | Mektovi, Lorbrena, Braftovi |
| Tersera Therapeutics LLC | $44.91 | 2023-2024 | Zoladex |
| Genzyme Corporation | $44.60 | 2023-2025 | |
| Taiho Oncology, INC. | $44.49 | 2023-2024 | |
| Novocure INC. | $43.07 | 2025 | Optune Lua (Novottf-200t) |
| Mirati Therapeutics, INC. | $41.67 | 2023 | Krazati |
| Ipsen Biopharmaceuticals, INC | $39.30 | 2024 | Onivyde |
| Telix Pharmaceuticals | $34.71 | 2024 | Illuccix |
| Springworks Therapeutics, INC. | $29.96 | 2024 | Ogsiveo |
| Foundation Medicine, INC. | $24.84 | 2023 | |
| Beigene USA, INC. | $22.11 | 2024 | Brukinsa |
| Kite Pharma, INC. | $21.65 | 2024 | Yescarta |
| Stemline Therapeutics INC. | $20.82 | 2023 | Orserdu |
| Apellis Pharmaceuticals, INC. | $17.75 | 2023 | Empaveli |
| Jazz Pharmaceuticals INC. | $17.27 | 2024 | |
| Ibsa Pharma INC. | $16.04 | 2023 | Tirosint, Licart |
| Tempus Ai, INC | $15.97 | 2024 | |
| Coherus Oncology, INC. | $15.04 | 2022 | |
| Sumitomo Pharma America, INC. | $13.77 | 2025 | Orgovyx |
| Morphosys, US INC. | $12.23 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Walz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.